Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

venetoclax 47Cyclophosphamide 43Specimen Handling 42Cytarabine 41fludarabine 32Biopsy 31Azacitidine 25Rituximab 20Methotrexate 17fludarabine phosphate 16blinatumomab 16Vincristine 15Daunorubicin 15Dexamethasone 14ibrutinib 13Whole-Body Irradiation 13Prednisone 13Magnetic Resonance Spectroscopy 13Injections 13obinutuzumab 11merphos 11Mercaptopurine 11Filgrastim 11Calcium Dobesilate 11asciminib 10X-Rays 10Stem Cell Transplantation 10Mycophenolic Acid 10Doxorubicin 10decitabine and cedazuridine drug combination 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
TAK-243 × Other hematologic neoplasm × 30 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡